• Metagenomi Therapeutics reported preclinical proof of concept for MGX-001, its potential one-time treatment for hemophilia A.
• A global clinical trial is planned for 2027, subject to regulatory clearance.
• MGX-001 is designed to insert a Factor VIII gene into the albumin locus for sustained Factor VIII production.
• Preclinical efficacy, safety and durability data will be presented at the American Society of Hematology meeting on December 14, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Metagenomi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611040925PRIMZONEFULLFEED9870142) on November 04, 2026, and is solely responsible for the information contained therein.